Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2721372 | 0.79 | IDO1 (0.60) | IDO1ENPP2PPARANPY5RNPBWR1 | |
| SCHEMBL970723 | 0.76 | IDO1 (0.61) | IDO1ENPP2NPBWR1 | |
| SCHEMBL2158677 | 0.76 | ENPP2 (0.61) | IDO1ENPP2MAPTLMNANPBWR1 | |
| SCHEMBL1440897 | 0.76 | IDO1 (0.53) | IDO1ENPP2MAPTNPBWR1 | |
| SCHEMBL23718811 | 0.76 | IDO1 (0.50) | IDO1ENPP2MAPTNPBWR1 | |
| SCHEMBL2731816 | 0.75 | PPARA (0.65) | IDO1ENPP2MAPTLMNAPPARA | |
| SCHEMBL17767949 | 0.74 | ENPP2 (0.59) | IDO1ENPP2PDPK1 | |
| Hydrochloric Acid SCHEMBL31070748 | 0.71 | PDPK1 (0.43) | IDO1ENPP2PDPK1 | |
| SCHEMBL6616481 | 0.71 | NPC1 (0.51) | MAPT | |
| SCHEMBL10066946 | 0.71 | METAP2 (0.44) | IDO1ENPP2LMNANPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| CN-121873041-A | Topiramate preparation method of special | 山东新时代药业有限公司 | 2026-04-17 | — | — | CN | disclosed |
| WO-2015035102-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-8858831-B2 | Scintillator compositions | STICHTING INCAS3 (NL) | 2014-10-14 | — | — | US | disclosed |
| US-20130270443-A1 | SCINTILLATOR COMPOSITIONS | STICHTING INCAS3 (NL) | 2013-10-17 | — | — | US | disclosed |
| EP-2468727-A1 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8183262-B2 | Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-7642264-B2 | Phenyl-substituted pyrimidine derivatives as mGluR antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GATTI MCARTHUR SILVIA | 2009-12-24 | — | — | US | disclosed |
| EP-2001849-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-5773592-A | COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED | MILLS RANDELL LEE (US) | 1998-06-30 | — | — | US | disclosed |
| US-5428163-A | Luminides; chemiluminescence; redox system, releasing free drug | MILLS RANDELL L (US) | 1995-06-27 | — | — | US | disclosed |
| US-5395838-A | Aromatic aminomethyl substitutes compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-03-07 | — | — | US | disclosed |
| US-5252573-A | Quinazoline derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-12 | — | — | US | disclosed |
| EP-0414730-A4 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | — | 1993-06-16 | — | — | EP | disclosed |
| US-5089499-A | Anticarcinogenic agents; thymidylate synthetase inhibitors; antiallergens; psoriasis | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-02-18 | — | — | US | disclosed |
| EP-0414730-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | Mills, Randell L. (US) | 1991-03-06 | — | — | EP | disclosed |
| WO-1989009833-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | MILLS RANDELL L (US) | 1989-10-19 | — | — | WO | disclosed |
| EP-0074229-B1 | TRIAZOLE GASTRIC ANTI-SECRETORY AGENTS | PFIZER INC. (US) | 1986-04-09 | — | — | EP | disclosed |
| EP-0074229-A1 | Triazole gastric anti-secretory agents | PFIZER INC. (US) | 1983-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | IDO1 1826/4885ENPP2 687/4885MAPT 2279/4885 |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GRM2, GRM1, GRM3 | IDO1 2505/4885ENPP2 966/4885MAPT 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.